Interview: Janssen R&D head Hait explains J&J's new platforms
This article was originally published in Scrip
Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has three new platforms that it's integrating into its existing therapeutic areas to shift the focus of R&D from disease treatment to prevention, according to global head of Janssen R&D William Hait.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.